Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.9433
- Book/Share 32.312
- PB 5.9798
- Debt/Equity 0.6469
- CurrentRatio 1.0059
- ROIC 0.1272
- MktCap 465339236848.0
- FreeCF/Share 6.7516
- PFCF 28.3795
- PE 18.6812
- Debt/Assets 0.2625
- DivYield 0.0263
- ROE 0.3369
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys
Published: October 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Read More
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
Read More
J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.
Read More
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
Read More
Johnson & Johnson's MedTech spin-off could boost focus, Bank of America says
Published: October 15, 2025 by: Proactive Investors
Sentiment: Positive
Bank of America maintained a ‘Neutral' rating on Johnson & Johnson (NYSE:JNJ) after the company posted third-quarter results slightly above expectations and hinted at a strategic MedTech shake-up. In a note Wednesday, the bank highlighted that J&J's third-quarter revenue and earnings per share beat consensus by roughly 1%, driven largely by stronger-than-expected performance from its Stelara biologic.
Read More
Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off
Published: October 15, 2025 by: MarketBeat
Sentiment: Neutral
Johnson & Johnson's NYSE: JNJ stock price can continue to advance because its strategy to reinvigorate growth and widen margins is working. The plan centers on divesting underperforming healthcare businesses to focus on higher-margin, more potent growth markets.
Read More
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
Read More
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Published: October 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wolk - Executive VP & CFO Jennifer Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Tim Schmid - Executive VP & Worldwide Chairman of MedTech John Reed - Executive Vice President of Innovative Medicine, R&D Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Danielle Antalffy - UBS Investment Bank, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo …
Read More
3 Dividend Aristocrats to Buy that Continued to Beat the Market
Published: October 14, 2025 by: 24/7 Wall Street
Sentiment: Positive
Finding top dividend stocks to invest in is one thing. Finding companies that can pay that dividend for years, and potentially decades, to come is a whole other story.
Read More
Compared to Estimates, Johnson & Johnson (JNJ) Q3 Earnings: A Look at Key Metrics
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Johnson & Johnson Stock Brushes Off Beat-and-Raise
Published: October 14, 2025 by: Schaeffers Research
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter.
Read More
Johnson & Johnson reports Q3 beat, plans orthopaedics spin-off
Published: October 14, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) posted third-quarter revenue and earnings that beat Wall Street estimates, driven by strength in its pharmaceuticals and medical devices businesses. The healthcare giant reported revenue of $23.99 billion for the quarter, up 6.8% from a year ago and slightly above analysts' expectations of $23.74 billion.
Read More
Is J&J's MedTech Segment Set for Another Quarter of Growth?
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.
Read More
RTW Investments' Rod Wong: Expect more deals in biotech space
Published: October 10, 2025 by: CNBC Television
Sentiment: Positive
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the sector, and much more.
Read More
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Read More
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Published: October 10, 2025 by: Reuters
Sentiment: Positive
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Read More
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
Published: October 10, 2025 by: WSJ
Sentiment: Positive
The two companies are already codeveloping a treatment for ulcerative colitis.
Read More
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Goldman Sachs expects another quarter of outperformance from J&J in Q3
Published: October 08, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ)'s strong year-to-date performance is likely to continue when the healthcare giant reports third quarter earnings on October 14, according to analysts at Goldman Sachs. The firm wrote in a note to clients that the stock's 31% gain this year, which is more than double the S&P 500's 14% rise, reflects “impressive execution across the Innovative Medicines segment,” which has driven sales and earnings estimates higher relative to peers.
Read More
Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Read More
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
Published: October 06, 2025 by: MarketBeat
Sentiment: Neutral
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
Read More
2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own
Published: October 03, 2025 by: 24/7 Wall Street
Sentiment: Positive
Retirees and older individuals are among the biggest demographics who tune into Jim Cramer's Mad Money show.
Read More
Why JNJ Stock Defines Shareholder Supremacy In Healthcare
Published: September 30, 2025 by: Forbes
Sentiment: Positive
Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder value has translated into exceptional market performance in 2025, with the stock delivering a remarkable 26% year-to-date return, significantly outpacing the broader healthcare sector and demonstrating the defensive strength that has made JNJ a cornerstone holding for income-focused investors.
Read More
3 Ultra-Safe Dividend Stocks to Buy Now, If You're Concerned About Volatility Ahead
Published: September 30, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors who find themselves awake at night thinking about their portfolios, fear not.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100